About the Company
We do not have any company description for Tevogen Bio Holdings Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Tevogen Bio Holdings Inc.
Tevogen Recognized in BINJE’s BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma
Tevogen Bio Holdings Inc. (“Tevogen” or the “Company”) (Nasdaq: TVGN), announced today that it has been named in BINJE’s BEST ...
REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts
Includes $36 million line of credit and potential $14 million private placement WARREN, N.J., Aug. 19, 2025 (GLOBE NEWSWIRE) ...
Tevogen CEO Donates Personal Shares to Support Brain Injury Recovery
Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced that Founder and CEO of Tevogen, Dr. Ryan ...
Tevogen Bio To Provide Timelines Associated with Recently Announced ...
WARREN, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the ...
Tevogen Bio Inc: Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum
Expenses significantly lower with expansion on multiple efforts; Q2 2025 loss from operations reduced to $5.4 million vs $8.6 million in Q2 2024.Tevogen maximizes capital efficiency, maintains access ...
Tevogen Bio Holdings Inc. Announces Letter of Intent with CD8 ...
Tevogen Bio Holdings Inc. announced that CD8 Technology Services LLC has signed a letter of intent to design a facility that will support Tevogen’s cell therapy manufacturing efforts.
Tevogen Bio Holdings Inc. to Provide Key Updates Ahead of Annual ...
Tevogen Bio Holdings Inc. announced it will provide several updates to stockholders prior to its Annual Meeting set for June 23, 2025. The updates will cover various aspects of the company's ...
Tevogen Bio Reaffirms Investor Confidence with Estimated Asset Value Exceeding $10 Billion
Tevogen Bio Holdings Inc. ('Tevogen” or the 'Company) (Nasdaq: TVGN), reiterates investor confidence and estimated asset ...
Cell Therapy Company Tevogen Bio Holdings Inc. (Nasdaq: TVGN) Rings ...
WARREN, N.J.--(BUSINESS WIRE)--Tevogen Bio Holdings Inc. ('Tevogen Bio') (Nasdaq: TVGN) celebrated commencement of its public trading by ringing the opening bell at the Nasdaq Stock Exchange in ...
Tevogen Bio Holdings Inc., a Cell Therapy Company, Announces Completion ...
Listing on Nasdaq is expected to provide Tevogen Bio Holdings Inc. increased access to capital to accelerate development of its genetically unmodified off-the-shelf T cell therapy products for ...
Tevogen Bio Holdings Inc. (TVGN): AI Innovations in Immunotherapy
Tevogen Bio Holdings Inc. (NASDAQ:TVGN) is a clinical-stage immunotherapy company focused on developing precision T-cell therapies using CD8+ cytotoxic T lymphocytes to treat infectious diseases ...
Similar Companies
Loading the latest forecasts...